10-QPeriod: Q3 FY2018

BRISTOL MYERS SQUIBB CO Quarterly Report for Q3 Ended Sep 30, 2018

Filed October 25, 2018For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) reported its third-quarter 2018 results, showing continued revenue growth driven by key products. While the company faces ongoing challenges, particularly related to patent expirations and competitive pressures in certain therapeutic areas, its strategic focus on innovative biopharmaceuticals and pipeline development remains a central theme. Investors should pay close attention to the performance of its established growth drivers and the progress of its late-stage pipeline assets, which are crucial for future revenue sustainability and expansion. The company's financial performance reflects a complex operational environment. Revenue streams are being impacted by both the success of newer drugs and the decline of older ones. Management's discussion and analysis will likely provide further color on the specific product dynamics and the company's outlook for the remainder of the year and beyond, including any potential impacts from ongoing litigation or regulatory developments.

Financial Highlights

58 data points
Beta

Revenue

$5.69B

71.4% Gross Margin

Net Income

$1.90B

33.4% Net Margin

EPS (Diluted)

$1.16

Total Assets

$33.73B

Cash & Equivalents

$5.41B

Free Cash Flow

$1.05B

Financial Statements
Beta
Revenue$5.69B
Cost of Revenue$1.65B
Gross Profit$4.06B
R&D Expenses$1.28B
SG&A Expenses$1.10B
Operating Expenses$3.52B
Interest Expense$44.00M
Net Income$1.90B
EPS (Basic)$1.16
EPS (Diluted)$1.16
Shares Outstanding (Basic)1.63B
Shares Outstanding (Diluted)1.64B

Key Highlights

  • 1Revenue growth was reported for the nine months ended September 29, 2018, compared to the prior year period.
  • 2Key products like Opdivo and Eliquis continue to be significant drivers of revenue growth.
  • 3The company is actively managing its product portfolio, with some established products experiencing declines.
  • 4Research and development expenses remain a substantial investment, reflecting the company's commitment to pipeline advancement.
  • 5The filing details liquidity and capital resources, indicating the company's ability to fund operations and strategic initiatives.
  • 6The company acknowledges various risks and uncertainties, including those related to intellectual property, clinical trial outcomes, and market competition.

Frequently Asked Questions

While specific Q3 figures are detailed within the full 10-Q, the filing indicates overall revenue growth for the nine-month period. Key products such as Opdivo (nivolumab) and Eliquis (apixaban) have been consistently highlighted as major contributors to revenue expansion for Bristol Myers Squibb.

The filing points to several challenges, including the impact of patent expirations on older products, increasing competition within key therapeutic areas, and the inherent risks associated with drug development, such as clinical trial success and regulatory approvals. Legal proceedings and market risks are also noted.

The company continues to make significant investments in research and development (R&D) as detailed in the financial statements. This investment is directed towards advancing its pipeline of innovative biopharmaceuticals across various disease areas, which is crucial for sustaining long-term growth and offsetting potential revenue declines from mature products.

The filing includes information on the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, which provide insights into the company's liquidity and capital resources. Management's Discussion and Analysis section typically elaborates on the company's ability to meet its short-term and long-term financial obligations and fund its operations and strategic investments.